Tuesday, 20 October 2026European Markets

SEQUANA MEDICAL Stock Bearish Momentum With A 28% Slide So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of SEQUANA MEDICAL (BEL 20: SEQUA.BR) dropped by a staggering 28.46% to €3.62 at 11:21 EST on Tuesday, after two consecutive sessions in a row of losses. BEL 20 is sliding 0.64% to €3,808.21, after two sequential sessions in a row of gains. This seems, up to now, a somewhat down trend exchanging session today.

SEQUANA MEDICAL's last close was €5.00, 33.33% below its 52-week high of €7.50.

About SEQUANA MEDICAL

Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.

Earnings Per Share

As for profitability, SEQUANA MEDICAL has a trailing twelve months EPS of €-1.29.

Revenue Growth

Year-on-year quarterly revenue growth grew by 31.8%, now sitting on 923k for the twelve trailing months.

Yearly Top and Bottom Value

SEQUANA MEDICAL's stock is valued at €3.62 at 11:21 EST, way under its 52-week low of €4.82.

Moving Average

SEQUANA MEDICAL's worth is way below its 50-day moving average of €5.31 and way below its 200-day moving average of €5.90.

More news about SEQUANA MEDICAL (SEQUA.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Sovereign, Local and Open AI: Infrastructure and Applied Intelligence Scale Up While Frontier-Lab Safety Scrutiny Grows
AI is shifting from cloud-rented models toward locally run, owned and open intelligence. ASUS/NVIDIA RTX Spark laptops pair with Nous Research's Hermes and ComfyUI, and Microsoft pushes hybrid local/cloud Windows. Cisco, NVIDIA and Marvell build open high-bandwidth AI infrastructure, and Hesai supplies real-world data for physical AI. In finance and commerce, Intuit, Zeta, Parloa/TELUS Digital and Snipp embed agentic AI into trusted financial and customer workflows, while OpenAI's math breakthroughs, its security disclosures and an executive's departure from its safety role keep safety and governance scrutiny high.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,397 source documents archived
Query this data → isubstrate.com